101. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression
- Author
-
Toyoharu Kamibeppu, Shoichiro Mukai, Satoru Sugie, Hiromasa Tsukino, Koji Yamasaki, and Toshiyuki Kamoto
- Subjects
0301 basic medicine ,Male ,Cancer Research ,medicine.medical_treatment ,Bone Neoplasms ,Enzyme-Linked Immunosorbent Assay ,urologic and male genital diseases ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Proto-Oncogene Proteins ,parasitic diseases ,LNCaP ,medicine ,Biomarkers, Tumor ,Tumor Cells, Cultured ,Humans ,Protein Precursors ,Receptor ,neoplasms ,Cells, Cultured ,Aged ,Retrospective Studies ,Chemistry ,Hepatocyte Growth Factor ,Growth factor ,Serine Endopeptidases ,Cancer ,Bone metastasis ,Receptor Protein-Tyrosine Kinases ,Cell Biology ,Middle Aged ,Proto-Oncogene Proteins c-met ,medicine.disease ,Prostatic Neoplasms, Castration-Resistant ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer cell ,Immunology ,Cancer research ,Disease Progression ,Hepatocyte growth factor ,medicine.drug ,Signal Transduction - Abstract
Hepatocyte growth factor (HGF) is a well-known multifunctional growth factor, and evidence has accumulated indicating that the HGF/MET (HGF receptor) signaling axis is involved in the progression of cancer. Macrophage-stimulating protein (MSP) is also known as a growth factor which activates not only macrophages but also cancer cells and osteoclasts through the activation of the specific Receptor d’origine nantais (RON). Pro-HGF and pro-MSP lack biological activity and, therefore, require proteolytic activation for conversion to an active two-chain form by HGF activator (HGFA). Although, there are several studies on HGF/MET signaling with castration-resistant prostate cancer (CRPC) and bone metastasis, reports on plasma protein are rare. In addition, the MSP/RON signaling axis in PC is not well understood. Here, we analyzed associations between PC progression and plasma HGF and MSP levels. We tested plasma samples from 58 patients with PC: 36 with castration-resistant (CR) PC and 22 with pretreatment for PC as control. We used enzyme-linked immunosorbent assay (ELISA) kit to determine plasma levels of HGF, MSP and HGFA, and examined correlations with clinicopathological characteristics such as Gleason grade and bone metastasis. PCR was used to evaluate HGF and MSP-related molecules in PC cell lines. Plasma levels of HGF, MSP and HGFA in the CRPC group were higher than in the control group (HGF: P
- Published
- 2015